Suven Life Sciences Limited has informed the Exchange regarding Investor Presentation
SUVEN Life Sciences Ltd
Communication to investors December 2018
5-Feb-19
2018-19 Q3 results
Risk statement
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.
5-Feb-19
2018-19 Q3 results
FINANCIAL QUICK VIEW
FY 2018-19 Q3 to Q2
FY 2018-19 YoY 9 months
Growth in revenue
Growth in Pre-R&D EBIDTA
40.24%
27.66%
1.20%
-8.18%
Growth in EBIDTA
33.41%
-10.92%
Growth in PAT
R&D to sales
Increase in R&D Costs
40.27%
-14.57%
10.41%
13.27%
9.85%
2.06%
5-Feb-19
2018-19 Q3 results
MAJOR PROFITABILITY RATIOS
Pre-R&D EBITDA to Income
EBIDTA to Income
Q3 Dec 18
9 months- Dec 18
41.10%
42.06%
30.69%
32.21%
PAT to Income
18.67%
19.01%
Cash Flow to Income
22.83%
22.88%
5-Feb-19
2018-19 Q3 results
Q3 to Q2 COMPARISON
Current quarter to previous quarter
Revenue - INR Million
PAT - INR Million
1,347.83
961.08
251.65
179.41
300.00
250.00
200.00
150.00
100.00
Q2 Sep 17
Q3 Dec 17
Q2 Sep 17
Q3 Dec 17
EBIDTA - INR Million
Pre-R&D EBIDTA - INR Million
413.59
310.01
553.90
433.88
650.00
550.00
450.00
350.00
250.00
150.00
50.00
Q2 Sep 17
Q3 Dec 17
Q2 Sep 17
Q3 Dec 17
1,600.00
1,100.00
600.00
100.00
450.00 400.00 350.00 300.00 250.00 200.00 150.00 100.00
5-Feb-19
2018-19 Q3 results
REVENUE COMPARISON
INR Million
Year on year
4,255.80
4,306.81
1,669.47
1,347.83
5,000.00
4,500.00
4,000.00
3,500.00
3,000.00
2,500.00
2,000.00
1,500.00
1,000.00
500.00
-
Q3 Dec 17
Q3 Dec 18
9M Dec 17
9M Dec 18
5-Feb-19
2018-19 Q3 results
PAT COMPARISON
INR Million
Year on year
958.43
818.78
1,200.00
1,000.00
800.00
600.00
400.00
345.74
251.65
200.00
-
Q3 Dec 17
Q3 Dec 18
9M Dec 17
9M Dec 18
5-Feb-19
2018-19 Q3 results
EBIDTA COMPARISON
INR Million
Year on year
1,557.19
1,387.19
546.81
413.59
1,800.00
1,600.00
1,400.00
1,200.00
1,000.00
800.00
600.00
400.00
200.00
-
Q3 Dec 17
Q3 Dec 18
9M Dec 17
9M Dec 18
5-Feb-19
2018-19 Q3 results
R & D – EXPENDITURE
Year on year
INR Million
415.52
424.07
138.78
140.31
450.00
400.00
350.00
300.00
250.00
200.00
150.00
100.00
50.00
-
Q3 Dec 17
Q3 Dec 18
9M Dec 17
9M Dec 18
5-Feb-19
2018-19 Q3 results
PRE-R&D EBIDTA
INR Million
Year on year
1,972.70
1,811.26
685.59
553.90
2,500.00
2,000.00
1,500.00
1,000.00
500.00
-
Q3 Dec 17
Q3 Dec 18
9M Dec 17
9M Dec 18
5-Feb-19
2018-19 Q3 results
PRE-R&D CASHFLOW
Year on year
INR Million
1,800.00
1,600.00
1,400.00
1,200.00
1,000.00
800.00
1,533.43
1,409.63
600.00
538.69
448.05
400.00
200.00
-
Q3 Dec 17
Q3 Dec 18
9M Dec 17
9M Dec 18
5-Feb-19
2018-19 Q3 results
FINANCIAL SNAPSHOT
All figures are in INR Million, other than ratios and EPS
Income Pre-R&D EBITDA
Pre-R&D EBITDA Margin EBITDA EBITDA Margin EBIT EBIT Margin Financing costs Taxes Net Profit after tax NP Margin
EPS (basic & diluted not annualised)
Paid up share capital (One Rupee Share) Depreciation R&D expenses
2018-19 Q3
2018-19 Q2
Growth %
2017-18 Q3
Growth %
2018-19 9 mons
2017-18 9 mons
Growth %
1,347.83 553.90
961.08 40.24% 1,669.47 -19.27% 4,306.81 685.59 -19.21% 1,811.26 433.88 27.66%
4,255.80 1,972.70
1.20% -8.18%
310.01 33.41%
253.71 40.64%
41.10% 45.15% 413.59 30.69% 32.26% 356.81 26.47% 26.40% 5.91 68.40
5.29 99.87 251.65 18.67% 18.67%
179.41 40.27%
42.06% 41.07% 546.81 -24.36% 1,387.19 32.75% 32.21% 492.40 -27.54% 1,218.34 28.29% 29.49% 21.88 11.52 135.15 377.68 345.74 -27.22% 818.78 19.01% 20.71%
46.35% 1,557.19 36.59% 1,396.97 32.83% 33.58 404.96 958.43 22.52%
-10.92%
-12.79%
-14.57%
1.98
1.41
2.72
6.45
7.54
127.28 56.09 140.31
127.28 55.61
123.87 13.27%
127.28 54.17 138.78
127.28
127.28
166.78 1.10% 424.07
159.49 415.52
2.06%
5-Feb-19
2018-19 Q3 results
News Release
• During the period Suven secures 4 product
patents covering Brasil, Eurasia, Australia and Singapore
• Suven presented in B&K Investor Conference -
Emergent India in December 2018
• The Board has proposed an Interim Dividend of Re. 1.50 per share (150% of face value of Rs. 1.00 each)
5-Feb-19
2018-19 Q3 results
News Release
• Suven Board approved of demerger of Contract Research and Manufacturing Services (CRAMS) undertaking of Suven Life Sciences Limited (SLSL) into Suven Pharmaceuticals Limited (SPL), through a scheme of arrangement, subject to approval of respective regulatory authorities. More details will be notified separately
5-Feb-19
2018-19 Q3 results